• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

呼吸道合胞病毒与皂苷QS-21的纯化融合蛋白制剂在Balb/c小鼠中诱导出的保护性免疫反应,与实验性感染所产生的免疫反应相似。

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.

作者信息

Hancock G E, Speelman D J, Frenchick P J, Mineo-Kuhn M M, Baggs R B, Hahn D J

机构信息

Department of Immunology, Lederle-Praxis Biologicals, Inc., West Henrietta, NY 14586-9728, USA.

出版信息

Vaccine. 1995 Mar;13(4):391-400. doi: 10.1016/0264-410x(95)98263-a.

DOI:10.1016/0264-410x(95)98263-a
PMID:7793137
Abstract

The feasibility of employing a vaccine composed of the purified fraction 21 of Quillaja saponaria (QS-21) and the fusion (F) protein of respiratory syncytial virus (RSV) to induce protective immune responses in the lower respiratory tract of Balb/c mice was examined. Our goal was to compare local and systemic immune responses with those induced following immunization with the protein adsorbed to aluminium hydroxide (F/ALOH) adjuvant or by experimental infection. Sera from mice vaccinated with the QS-21 formulation (F/QS-21) contained elevated anti-F protein IgG antibody titres that were dependent on the dose of QS-21 employed. Similar to the immune responses generated by experimental infection, the sera from mice vaccinated with F/QS-21 possessed greater capacity to neutralize virus infectivity that was associated with the generation of heightened complement-fixing IgG2a antibody titres. In contrast, vaccination with F/ALOH elicited systemic immune responses that were characterized by a predominance of protein-specific antibodies of the IgG1 subclass and lower neutralizing antibody titres. The capacity of F/QS-21 to facilitate local pulmonary immune responses was also examined and found to be similar to those induced by experimental infection. After virus challenge, a 90-fold increase in the number of F protein-specific antibody-secreting cells was observed and associated with the clearance of virus from the infected lungs. Moreover, elevated levels of antigen-dependent killer cell activity were detected and appeared to be mediated by class I major histocompatibility complex restricted CD8+ T cells. Additional characterization of the pulmonary immune response was performed on the cellular infiltrates obtained after bronchoalveolar lavage and on formalin-fixed lung tissue. The local protective immune responses induced after challenge of the groups immunized with F/QS-21 or infectious virus were significantly different from those elicited in naive control mice injected with adjuvant alone, or in mice immunized with F/ALOH. The cellularity of the lavage fluids from the former groups was characterized by a significantly greater percentage of lymphocytes and less neutrophils. In similar fashion histological evaluation of the lungs from mice immunized with F/QS-21 or infectious virus revealed significantly elevated local immune responses after challenge. In conclusion, the results suggest that formulation with F/QS-21 alters the qualitative and quantitative nature of the immune response to the F glycoprotein when compared with the traditional aluminium-based adjuvants.

摘要

研究了使用由皂树(Quillaja saponaria)纯化的21组分(QS-21)和呼吸道合胞病毒(RSV)融合(F)蛋白组成的疫苗在Balb/c小鼠下呼吸道诱导保护性免疫反应的可行性。我们的目标是将局部和全身免疫反应与用吸附于氢氧化铝(F/ALOH)佐剂的蛋白免疫或实验性感染后诱导的免疫反应进行比较。用QS-21制剂(F/QS-21)接种的小鼠血清中,抗F蛋白IgG抗体滴度升高,这取决于所用QS-21的剂量。与实验性感染产生的免疫反应相似,用F/QS-21接种的小鼠血清具有更强的中和病毒感染性的能力,这与补体结合IgG2a抗体滴度升高有关。相比之下,用F/ALOH接种引发的全身免疫反应的特征是IgG1亚类的蛋白特异性抗体占优势且中和抗体滴度较低。还研究了F/QS-21促进局部肺部免疫反应的能力,发现其与实验性感染诱导的能力相似。病毒攻击后,观察到F蛋白特异性抗体分泌细胞数量增加了90倍,这与病毒从感染的肺部清除有关。此外,检测到抗原依赖性杀伤细胞活性水平升高,似乎由I类主要组织相容性复合体限制的CD8+T细胞介导。对支气管肺泡灌洗后获得的细胞浸润物和福尔马林固定的肺组织进行了肺部免疫反应的进一步表征。用F/QS-21或传染性病毒免疫的组在攻击后诱导的局部保护性免疫反应与单独注射佐剂的未免疫对照小鼠或用F/ALOH免疫的小鼠引发的反应明显不同。前一组支气管肺泡灌洗液的细胞组成特征是淋巴细胞百分比显著更高,中性粒细胞更少。以类似方式,对用F/QS-21或传染性病毒免疫的小鼠的肺进行组织学评估显示,攻击后局部免疫反应显著升高。总之,结果表明,与传统的铝基佐剂相比,F/QS-21制剂改变了对F糖蛋白免疫反应的质量和数量性质。

相似文献

1
Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.呼吸道合胞病毒与皂苷QS-21的纯化融合蛋白制剂在Balb/c小鼠中诱导出的保护性免疫反应,与实验性感染所产生的免疫反应相似。
Vaccine. 1995 Mar;13(4):391-400. doi: 10.1016/0264-410x(95)98263-a.
2
Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.用呼吸道合胞病毒天然附着(G)糖蛋白免疫BALB/c小鼠后产生非典型肺部炎症反应。
J Virol. 1996 Nov;70(11):7783-91. doi: 10.1128/JVI.70.11.7783-7791.1996.
3
The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus.用呼吸道合胞病毒融合蛋白接种的Balb/c小鼠的肺部免疫反应。
Vaccine. 1994;12(3):267-74. doi: 10.1016/0264-410x(94)90204-6.
4
The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.与氢氧化铝佐剂和重组白细胞介素-12共同配制后呼吸道合胞病毒亚单位疫苗的免疫原性。
Viral Immunol. 2000;13(1):57-72. doi: 10.1089/vim.2000.13.57.
5
QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus.QS-21与重组白细胞介素-12协同作用,为呼吸道合胞病毒融合蛋白打造一种强效佐剂配方。
Viral Immunol. 2000;13(4):503-9. doi: 10.1089/vim.2000.13.503.
6
Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.先前用嵌合呼吸道合胞病毒(RSV)融合糖蛋白免疫的棉鼠,在感染RSV时会出现肺部病理变化加重的情况,而在用痘苗-RSV重组体或RSV免疫后则不会出现这种现象。
Vaccine. 1992;10(7):475-84. doi: 10.1016/0264-410x(92)90397-3.
7
CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).含CpG的寡脱氧核苷酸是呼吸道合胞病毒(RSV)融合(F)蛋白进行肠胃外疫苗接种的有效佐剂。
Vaccine. 2001 Sep 14;19(32):4874-82. doi: 10.1016/s0264-410x(01)00228-6.
8
Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.用聚磷酸酯纳米粒包裹呼吸道合胞病毒融合蛋白、CpG 寡脱氧核苷酸和先天防御调节肽后免疫的增强作用及其对呼吸道合胞病毒的保护作用。
Vaccine. 2012 Jul 27;30(35):5206-14. doi: 10.1016/j.vaccine.2012.06.011. Epub 2012 Jun 17.
9
Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.呼吸道合胞病毒(RSV)G蛋白可溶性重组片段的脂质体包封可增强免疫保护作用,并减少与病毒攻击相关的肺部嗜酸性粒细胞增多。
Vaccine. 2000 Jan 6;18(11-12):1110-7. doi: 10.1016/s0264-410x(99)00373-4.
10
Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.使用纯化的F蛋白和基因解毒霍乱全毒素CT-E29H对呼吸道合胞病毒进行有效的黏膜免疫。
Vaccine. 2000 Jun 1;18(24):2723-34. doi: 10.1016/s0264-410x(00)00058-x.

引用本文的文献

1
Shatavarin-IV saponin adjuvant elicits IgG and IgG2b responses against bacterin in a murine model.印度人参-IV皂苷佐剂在小鼠模型中引发针对菌苗的IgG和IgG2b应答。
Heliyon. 2023 Apr 11;9(4):e15339. doi: 10.1016/j.heliyon.2023.e15339. eCollection 2023 Apr.
2
A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.一种重组无锚定呼吸道合胞病毒(RSV)融合(F)蛋白/单磷酰脂质 A(MPL)疫苗可预防 RSV 引起的复制和肺部病理。
Vaccine. 2014 Mar 14;32(13):1495-500. doi: 10.1016/j.vaccine.2013.11.032. Epub 2013 Nov 16.
3
Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch.
经皮接种微针贴片接种灭活轮状病毒疫苗可减少剂量并增强免疫原性。
Vaccine. 2013 Jul 25;31(34):3396-402. doi: 10.1016/j.vaccine.2012.11.027. Epub 2012 Nov 19.
4
Respiratory syncytial virus vaccine: Is it coming?呼吸道合胞病毒疫苗:它会问世吗?
Paediatr Child Health. 2003 Dec;8(10):605-8. doi: 10.1093/pch/8.10.605.
5
Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.人类对含或不含QS21佐剂的灭活流感疫苗的体液免疫和细胞介导免疫反应。
Vaccine. 2007 Apr 30;25(17):3263-9. doi: 10.1016/j.vaccine.2007.01.073. Epub 2007 Jan 24.
6
Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.含CpG寡脱氧核苷酸的制剂可预防用福尔马林灭活或市售灭活牛呼吸道合胞病毒疫苗进行初次免疫后肺部免疫病理学的诱导。
J Virol. 2005 Feb;79(4):2024-32. doi: 10.1128/JVI.79.4.2024-2032.2005.
7
Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.对重组呼吸道合胞病毒的特性进行研究,这些病毒的附着(G)蛋白中负责2型T细胞应答和肺部嗜酸性粒细胞增多的区域已被删除。
J Virol. 2004 Aug;78(16):8446-54. doi: 10.1128/JVI.78.16.8446-8454.2004.
8
Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.缺乏附着(G)蛋白C端三分之一的重组呼吸道合胞病毒具有免疫原性,且在体内和体外均表现出减毒特性。
J Virol. 2004 Jun;78(11):5773-83. doi: 10.1128/JVI.78.11.5773-5783.2004.
9
Protection against respiratory syncytial virus infection by DNA immunization.DNA免疫对呼吸道合胞病毒感染的防护作用。
J Exp Med. 1998 Aug 17;188(4):681-8. doi: 10.1084/jem.188.4.681.
10
Respiratory syncytial virus vaccines.呼吸道合胞病毒疫苗
Clin Microbiol Rev. 1998 Jul;11(3):430-9. doi: 10.1128/CMR.11.3.430.